The Leukemia & Lymphoma Society’s Therapy Acceleration Program (TAP) is a venture capital fund targeting the biotech and health tech sectors to combat blood cancers. TAP funds companies focused on cancer research, aiming to transform lab discoveries into practical patient solutions. Notable investments include Enterome. By driving the development of new therapies, TAP strives to accelerate the availability of effective treatments for blood cancer patients.
